Pre-made Tigatuzumab biosimilar ( Whole mAb, anti-TNFRSF10B therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-571
Anti-TNFRSF10B therapeutic antibody (Pre-made Tigatuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-TNFRSF10B therapeutic antibody (Pre-made Tigatuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Daiichi Sankyo Company;University of Alabama at Birmingham|
|Conditions Discontinued||Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer|